Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis

James W. Verbsky, Andrew J. White

Research output: Contribution to journalArticle

156 Scopus citations

Abstract

Systemic onset juvenile rheumatoid arthritis (SOJRA) is a multisystem disease characterized by high fever, rash, arthritis, serositis, splenomegaly, and laboratory evidence of systemic inflammation. Anticytokine therapies show promise in the treatment of chronic arthritides in children. We describe the use of the recombinant interleukin 1 receptor antagonist anakinra in 2 patients with therapy resistant SOJRA. Both patients experienced immediate and sustained resolution of symptoms and laboratory markers of inflammation, in one case after years of treatment with other immunosuppressive therapies.

Original languageEnglish
Pages (from-to)2071-2075
Number of pages5
JournalJournal of Rheumatology
Volume31
Issue number10
StatePublished - Oct 1 2004

Keywords

  • Anakinra
  • Hemophagocytic syndrome
  • Infliximab
  • Juvenile onset still disease
  • Juvenile rheumatoid arthritis

Fingerprint Dive into the research topics of 'Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis'. Together they form a unique fingerprint.

  • Cite this